Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
An independent verification briefing examining Sprout Health NAD+ compounding status, FDA classification, pricing, and enrollment considerations.
-
Informational overview of Sprout Health's compounded GLP-1 telehealth model, semaglutide and tirzepatide pricing, and FDA status for 2026.
-
Sprout Health lists prescription NAD+ injections at $149 first month through telehealth platform as consumer interest in compounded NAD+ grows.
-
As 2026 approaches, an industry analysis examines GLP-1 telehealth access, medications, and disclosure standards shaping management decisions.